Slide 1: ASX Announcement: 1H25 Investor Presentation Materials
ASX Announcement 20 February 2025 1H25 Investor Presentation Materials For personal use only Cogstate Ltd (ASX:CGS) has today released an Investor Briefing that provides a summary of the financial results for the half-year ended 31 December 2024 (1H25) and also provides commentary in respect of the
Slide 2: About Cogstate
About Cogstate Cogstate Ltd (ASX:CGS) is the neuroscience technology company optimising brain health assessments to advance the development of new medicines and to enable earlier clinical insights in healthcare. Cogstate technologies provide rapid, reliable and highly sensitive computerised cognitiv
Slide 3: Investor Update: Half Year Financial Results
For personal use only Investor Update Half Year Financial Results 20 February 2025 © 2025 Cogstate Ltd. All rights reserved.
Slide 4: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Cogstate Limited (‘Cogstate’). The information in this presentation is of a general na ture and does not purport to be complete, nor does it contain all the information which would be required in a prospectus prepared in accorda
Slide 5: 1H25 Business & Financial Highlights
1H25 Business & Financial Highlights all figures in US$ For personal use only 1. Strong financial performance • Record revenue, 61% gross margins, 20% EBIT margins, $5m positive operating cashflow • Margins over the last two half-year periods are consistent with pro-forma model 2. Higher than histor
Slide 6: 1H25 Financial Results
1H25 Financial Results (All figures in US$) For personal use only Clinical sales contracts executed Contracted future revenue $20.3m $99.1m Growth in both Alzheimer’s and other indications. +86% Clinical Trial backlog declined 8%. -20% Seeing an increased number of opportunities. Healthcare: Eisai a
Slide 7: Cogstate Group
For personal use only Cogstate Group 1H25 2H24 1H24 Highlights US$ millions Jul-Dec 2024 Jan-Jun 2024 Jul-Dec 2023 • Revenue growth resulting Revenue 23.9 23.2 20.2 from Clinical Trials, offset by decline in Healthcare Gross Profit 14.7 13.8 10.8 • Strong improvement in gross GP% 61% 59% 54% profit
Slide 8: Segments
Segments Highlights Clinical Trials (including Research) Clinical Trials For personal use only 1H25 2H24 1H24 US$ millions Jul-Dec 2024 Jan-Jun 2024 Jul-Dec 2023 • Growth in revenue resulting largely from in-period revenue Revenue 22.7 21.5 17.9 yield Direct Costs (excluding depreciation) (7.0) (6.7
Slide 9: Cash Flow
Cash Flow US$ millions 1H25 2H24 1H24 Highlights For personal use only Net Profit after Tax 3.9 3.4 2.0 • Increased receipts from Depreciation & Amortization 1.4 1.2 1.4 customers by $6.6m from Disposal of Assets 0.0 0.1 0.0 growth in Clinical Trials Non-cash employee benefits (0.1) 0.1 0.7 • The in
Slide 10: Clinical Trials Sales Contracts, by Half Year
Clinical Trials Sales Contracts, by Half Year 1H25 For personal use only 60 Clinical Trials Sales Contracts $20.3m 50 • Alzheimer’s $14.2m • 1H24 $6.7m 40 • 2H24 $4.1m US$ Million • Other indications $6.1m 30 • 1H24 $4.2m • 2H24 $11.9m 20 • Across all indications, seeing an increased number of oppor
Slide 11: Contracted Revenue Run-Off
Contracted Revenue Run-Off 45 For personal use only 40 1.1 35 16.3 Highlights 30 • $99.1m contracted future revenue US$ Millions 25 • $84.3m Clinical Trials 2.2 • $14.8m Healthcare 20 7.1 2.2 • $41.3m contracted FY25 revenue 15 2.2 • vs $36.7m PCP 23.9 • $17.4m 2H25 (vs $16.5m PCP) 10 21.5 16.7 16.4
Slide 12: CNS Clinical Trials Pipeline Momentum Continues to Build
CNS Clinical Trials Pipeline Momentum Continues to Build For personal use only • CNS market size forecasted to reach $230B by 2032 • Highest forecasted growth in AD; followed by PD, Mood, Migraine and other CNS • CNS accounted for an average of 15% of all product focused transactions in four of the
Slide 13: Partnership Spotlight
Partnership Spotlight For personal use only Medidata is the leading provider of SaaS and data analytics solutions for clinical research Partnership announced First award achieved Trained global team 29 Oct 2024 4 Dec 2024 10 Feb 2025 • Strong initial pipeline growth from Medidata across 28 unique cu
Slide 14: Cogstate Business Poised for Scale
Cogstate Business Poised for Scale For personal use only Workflow automations Enhanced offering for Data integrations for for leveraging clinician data insights and seamless delivery with network of global analytics channel partners consultant resources • Purpose built app to • Data management and •
Slide 15: Guidance for 2H25
Guidance for 2H25 For personal use only Clinical Trials Revenue: • 2H25 revenue is expected to be consistent with 1H25 revenue • Based on contracted revenue position at 01 January 2025 ($16.3m expected to be recognised in 2H25 vs $14.5m PCP) and high probability sales prospects • If sales contracts
Slide 16: For personal use only
For personal use only
Slide 17: Appendix - Medidata
Appendix - Medidata For personal use only • Founded in 1999, Medidata was acquired by French software company Dassault Systèmes in 2019 for US$5.8bn • Medidata is a leading provider of SaaS and data analytic solutions that support clinical research • Medidata’s EDC (electronic data capture) system,